Last updated: March 19, 2026
What Is NDC 51672-4117?
NDC 51672-4117 is a drug identified within the National Drug Code system. According to available data, it corresponds to Glatiramer Acetate, a medication primarily used for multiple sclerosis (MS) treatment.
Market Overview
Market Size
- Total global MS drug market estimated at USD 26 billion in 2022.
- Glatiramer Acetate accounts for approximately USD 4 billion in global sales, with significant sales in the U.S. and Europe.
- The U.S. market had sales of roughly USD 2.4 billion in 2022 for Glatiramer Acetate, constituting around 60% of global sales.
Competitive Landscape
- Key Brands: Copaxone (Teva), Glatopa (Mylan), generic formulations.
- Patent Status: Key patents expired or are expiring, leading to increased generic availability.
- Generic Competition: Multiple generics approved since 2018 in the U.S., increasing price competition.
Regulatory Status
- Approved by FDA since 1996.
- Several biosimilar and generic versions approved recently, driving downward pricing.
Pricing Dynamics
Current Pricing
| Formulation |
Average Wholesale Price (AWP) |
List Price per Dose |
| Brand (Copaxone 40 mg) (30 days) |
USD 3,300 |
USD 110 per dose |
| Generic versions (30 days supply) |
USD 1,300 – USD 1,800 |
USD 43 – USD 60 per dose |
Price Trends
- Original branded formulations cost USD 3,000–3,300 for a 30-day supply from 2016–2019.
- Licenses for generics and biosimilars have reduced prices by approximately 50% in the last 3–4 years.
- Prices are expected to decline further as more biosimilars enter the market.
Market Drivers
- Rising prevalence of MS globally, with estimates of 2.8 million cases in 2020.
- Increased adoption of generic and biosimilar formulations driven by patent expirations.
- Insurance coverage and reimbursement policies influence drug pricing and market penetration.
- Biologics and biosimilar market policies in the U.S. and Europe support price competition.
Price Projections (Next 5 Years)
| Year |
Expected Average Price (USD) |
Rationale |
| 2023 |
USD 1,200 |
Continued generic competition continuing to pressure prices |
| 2024 |
USD 1,050 |
Further biosimilar approvals enhance competition |
| 2025 |
USD 950 |
Market stabilizes with more biosimilars and cost containment |
| 2026 |
USD 900 |
Industry shifts toward more affordable options |
| 2027 |
USD 850 |
Potential introduction of new biosimilars and pricing strategies |
Key Factors Influencing Price Trends
- Patent Expirations: Expected acceleration of price declines as additional biosimilars are approved.
- Healthcare Policy: Price negotiations and reimbursement policies in the U.S. and Europe will significantly influence market prices.
- Manufacturing Costs: Generally stable, but reductions may occur as production efficiencies improve.
- Market Penetration: Increased adoption of generics will continue to suppress prices.
Risks and Barriers
- Regulatory hurdles for biosimilar approval could delay price reductions.
- Market resistance to switching from branded to generic formulations.
- Supply chain disruptions that could temporarily impact availability and pricing.
Key Takeaways
- The drug identified by NDC 51672-4117 is predominantly used for MS and has a large, mature market.
- Prices for its formulations are expected to decrease significantly over the next five years, driven by biosimilar and generic competition.
- The current average wholesale price for branded formulations is around USD 3,300 per 30-day supply, with generics at USD 1,300–USD 1,800.
- Projected prices by 2027 could approach USD 850–USD 900 per 30-day supply.
- Market dynamics are heavily influenced by patent status, regulatory approval of biosimilars, and healthcare policy.
FAQs
1. How soon will biosimilar versions significantly impact prices?
Biosimilars are set to increase market penetration, reducing prices towards 2024–2025 as approvals and market adoption expand.
2. What are the main drivers for price decline?
Patent expirations, increased biosimilar approvals, and policy-driven cost containment measures are primary drivers.
3. Are prices likely to rebound after decline?
Prices may stabilize or slightly increase if new formulations or innovations emerge, but downward pressure remains dominant.
4. How does insurance coverage affect the actual patient cost?
Reimbursements, co-pays, and insurance contracts determine patient out-of-pocket costs, which may be lower than wholesale prices.
5. What is the outlook for market share among competitors?
Branded formulations are losing market share to generics, which are projected to hold the majority of prescriptions within five years.
References
- MarketWatch. (2022). Global Multiple Sclerosis Drugs Market Size. [Online] Available at: https://www.marketwatch.com/
- IQVIA. (2022). Global MS Market Insights. [Online] Available at: https://www.iqvia.com/
- FDA. (2022). Approval Details for Biosimilars of Glatiramer Acetate. [Online] Available at: https://www.fda.gov/
- Generic Pharmaceutical Association. (2022). Impact of Generics on Drug Pricing. [Online] Available at: https://gpha.org/
- Centers for Disease Control and Prevention. (2020). Multiple Sclerosis Data & Statistics. [Online] Available at: https://www.cdc.gov/
